TickerTalks
Browse all tickers →
TickerTalks›$IBRX
IBIBRX

ImmunityBio, Inc.

$IBRX·$11B·Biotechnology·Healthcare
$9.18-8.2%YTD+385.1%1Y+262.8%
Price updated 7h ago·X counts updated 5d ago
IBIBRX
$IBRXImmunityBio, Inc.
$9.18-8.20%817 posts1.2×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $IBRX on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

817X posts · last 7 days
Sep 29Oct 11
Chatter Meter
1.2×
QuietNormal · 1×Loud

How loud $IBRX's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 90% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data25 posts analyzed · as of 2026-10-02

Sentiment is strongly bullish-activist — Dr. Soon-Shiong presented 20 years of cancer-vaccine work to 170+ at NIH/NCI, the sBLA PDUFA is set for January 6, 2027 for papillary-only NMIBC, and the Quilt-2.005 trial is fully enrolled. Shorts carry 15+ days-to-cover against a Soon-Shiong-locked 65% float, which the crowd frames as a squeeze setup. Only one voice counsels taking profits off the ~300% YTD run.

Read what X is saying about $IBRX

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $IBRX — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventAcceleratingAI verdict · as of 2026-10-02

The move is getting stronger, with heavier trading behind it.

ImmunityBio has 4x'd on ANKTIVA adoption — the Jan 6 2027 PDUFA sits ahead against a 125M-share short.

ImmunityBio is a late-stage cancer-vaccine and immunotherapy company led by Patrick Soon-Shiong. The flagship drug ANKTIVA is already approved for bladder cancer, and a supplemental filing with a Jan 6 2027 PDUFA date is the next big catalyst.

  • The commercial ramp is real: Q1 revenue grew 168% YoY as ANKTIVA bladder-cancer prescriptions compound — operating margin is still -185% because R&D is heavy, but revenue is finally showing up on the P&L.
  • The structural short setup is notable: 125M+ shares short against a float that's 65% insider-locked — if the Jan 6 PDUFA goes positive, that's a classic squeeze setup given how little actual float is tradeable.
  • At PS 51 and PE -8.3 the stock is pricing in meaningful ANKTIVA label expansion plus pipeline value — the comparable is Soon-Shiong himself continuing to buy, not any traditional multiple.

Nov 3 Q3 is the near-term read for ANKTIVA sales cadence; the Jan 6 2027 PDUFA is the real binary. A clean sBLA approval opens meaningful label expansion; a CRL or delay hits the stock hard given how extended it is.

Agrees with X sentimentThe thread has the right catalyst framework — Jan 6 PDUFA, Soon-Shiong NIH/NCI, structural short setup, insider-locked float — just understand a $9B market cap at 51x sales is pricing in a lot of expansion before the FDA actually acts.

What to watch: Nov 3 Q3 for ANKTIVA sales trajectory, pipeline updates, and cash runway. The Jan 6 2027 PDUFA on the supplemental filing is the real binary — a CRL is the hard invalidator.

On the calendar: 2027-01-06 — sBLA PDUFA

Read the AI verdict on $IBRX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops immunotherapy and cell therapy platforms targeting bladder, pancreatic, and lung cancers, plus infectious disease vaccines.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $IBRX.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $IBRX

Partial — Develops immunotherapy and cell therapy platforms targeting bladder, pancreatic, and lung cancers, plus infectious disease vaccines.

Top industry ETF

$IBBiShares Biotechnology ETF
+17.9%YTD
+31.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-8.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-44.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-185%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-4.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
51.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
139%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
93.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-1.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-0.22$-0.08-175.0%
Q1 2026May 7, 2026$-0.62$-0.08-675.0%
Q4 2025Feb 23, 2026$-0.06$-0.08+25.0%
Q3 2025Nov 4, 2025$-0.07$-0.10+30.0%
Next earningsTue, Nov 3·consensus EPS $-0.07

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$44.2M+167.6%99.5%-158%$-0.62$-77.1M
Q4 FY25$38.3M+407.0%88.9%-169%$-0.06$-71.2M
Q3 FY25$32.1M+425.1%87.1%-174%$-0.07$-69.7M
Q2 FY25$26.4M+2423.9%99.5%-270%$-0.10$-80.8M

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$225.7M$206.0M – $245.5M-$0.96-$0.99 – -$0.923
FY27$454.4M$260.0M – $648.9M-$0.14-$0.35 – $0.073
FY28$1.1B$815.5M – $1.4B$0.42$0.30 – $0.542
FY29$1.8B$1.3B – $2.5B$0.87$0.56 – $1.291
FY30$2.5B$1.9B – $3.5B$1.40$0.91 – $2.071

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.69%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+7.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+20.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 115.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today18.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.135-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellOct 5Barry J. SimonDirector25.0K sh$269KSellOct 2Cheryl CohenDirector81.1K sh$851KSellJul 2Cheryl CohenDirector131.2K sh$1.2MSellJul 1Christobel SeleckyDirector159.5K sh$1.4MSellJun 30Christobel SeleckyDirector1.0K sh$9KSellJun 29Christobel SeleckyDirector95.7K sh$862KSellJun 24Barry J. SimonDirector25.0K sh$197KSellJun 4Barry J. SimonDirector23.0K sh$165K
+ 11 other (6 awards · 5 exempts) in window

See when $IBRX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentAug 6SC 13D/A
AI summary

Cambridge Equities, LP 2 Check the appropriate box if a membe amended its 13D filing disclosing a beneficial ownership position of 24.7% in IBRX (IBRX) as of 2026-08-06. The filer indicated plans: purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that sec. This is a material ownership disclosure indicating significant shareholder interest that may signal activist or strategic intent. Investors should monitor for further 13D amendments, which could indicate evolving positions or demands on management.

8-KPress release / Reg FDJul 308-K — Item 7.01: Press release / Reg FD
AI summary

IBRX (IBRX) filed an 8-K under Reg FD (Item 7.01) on 2026-07-30, posting a press release to its website or furnishing it to the SEC. On July 29, 2026, ImmunityBio, Inc. (“ImmunityBio” or the “Company”) issued a press release announcing that the Emirates Drug Establishment (“EDE”) of the United Arab Emirates (“UAE”) has granted marketing authorization for ANKTIVA ® across two indic This is an informational disclosure furnished (not filed) and does not create new liability under the Exchange Act. Materiality depends on the content of the presentation.

8-KShareholder voteJun 108-K — Item 5.07: Shareholder vote
AI summary

ImmunityBio, Inc. held its 2026 Annual Meeting on June 9, 2026, with approximately 85% of outstanding shares represented. Stockholders re-elected all nine incumbent directors (including founder/CEO Patrick Soon-Shiong) and ratified Deloitte & Touche LLP as auditor for fiscal 2026. Routine governance for a founder-controlled company; high participation rate reflects institutional engagement.

8-KMaterial agreementMay 188-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

ImmunityBio, Inc. (IBRX) entered into an exclusive development and supply agreement with Japan BCG Laboratory (JBL) on May 14, 2026 for JBL to exclusively manufacture and supply the Tokyo-172 BCG strain for ImmunityBio's use in the U.S. and territories. ImmunityBio bears all development, clinical, and regulatory responsibilities for a 10-year initial term from FDA approval; no payments to JBL are due until approval, with at least 2 batches per year required post-approval. This agreement secures ImmunityBio's critical BCG supply chain ahead of anticipated commercial launch — a potentially material commercial enabler contingent on FDA approval.

+ 7 other (2 10-Qs · 2 earnings 8-Ks · 2 proxys · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumorsbusinesswire.com·16h agoFDA Expands ImmunityBio's Anktiva Label in Bladder Cancerzacks.com·2d agoImmunityBio Stock Climbs Thursday: What's Going On?benzinga.com·2d agoFDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Diseasebusinesswire.com·3d agoImmunityBio (NASDAQ:IBRX) vs. Monte Rosa Therapeutics (NASDAQ:GLUE) Financial Surveydefenseworld.net·6d ago

In themes

Explore the broader themes this ticker is being talked about under.

AI Precision Medicine

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALEC$NWBO$DNA$NVAX$CAI$RXRX$PCVX
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport